Search research articles
Contact Us
Filters
Showing results (51-60 of 136) with videos related to
Page
of 14
Sort By:
Oncotarget
|
October 28, 2015
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
David S Hong, Razelle Kurzrock, Gerald S Falchook, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Investigational New Drugs
|
April 26, 2014
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy
Mehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 4, 2014
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
Apostolia M Tsimberidou, Alexandra M Adamopoulos, Yang Ye, et al.
The Oncologist
|
October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
Siqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Research
|
October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 136) with videos related to
Sort By:
Page
of 14
Oncotarget
|
October 28, 2015
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
David S Hong, Razelle Kurzrock, Gerald S Falchook, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Investigational New Drugs
|
April 26, 2014
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy
Mehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 4, 2014
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
Apostolia M Tsimberidou, Alexandra M Adamopoulos, Yang Ye, et al.
The Oncologist
|
October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
Siqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Research
|
October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Page
of 14